Briacell Therapeutics Corp Stock Performance
| BCTXW Stock | USD 0.17 0.01 6.25% |
The firm shows a Beta (market volatility) of 0.98, which signifies possible diversification benefits within a given portfolio. BriaCell Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, BriaCell Therapeutics is expected to follow. At this point, BriaCell Therapeutics has a negative expected return of -0.31%. Please make sure to confirm BriaCell Therapeutics' coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to decide if BriaCell Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BriaCell Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in March 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
1 | BriaCell Therapeutics Faces Uncertain Financial Future - TipRanks | 11/01/2024 |
2 | BriaCell Provides Update to its Board of Directors | 11/25/2024 |
3 | BriaCell Therapeutics Announces Closing of 5.5 Million Public Offering - GlobeNewswire | 12/13/2024 |
| Begin Period Cash Flow | 21.3 M |
BriaCell |
BriaCell Therapeutics Relative Risk vs. Return Landscape
If you would invest 30.00 in BriaCell Therapeutics Corp on November 2, 2024 and sell it today you would lose (13.00) from holding BriaCell Therapeutics Corp or give up 43.33% of portfolio value over 90 days. BriaCell Therapeutics Corp is currently producing negative expected returns and takes up 11.7963% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than BriaCell, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BriaCell Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BriaCell Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BriaCell Therapeutics Corp, and traders can use it to determine the average amount a BriaCell Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0261
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BCTXW |
Estimated Market Risk
| 11.8 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BriaCell Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BriaCell Therapeutics by adding BriaCell Therapeutics to a well-diversified portfolio.
BriaCell Therapeutics Fundamentals Growth
BriaCell Stock prices reflect investors' perceptions of the future prospects and financial health of BriaCell Therapeutics, and BriaCell Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BriaCell Stock performance.
| Return On Equity | -2.06 | ||||
| Return On Asset | -1.26 | ||||
| EBITDA | (4.79 M) | ||||
| Net Income | (4.93 M) | ||||
| Total Debt | 8.56 M | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (24.13 M) | ||||
| Market Capitalization | 48.08 M | ||||
| Total Asset | 5.87 M | ||||
| Retained Earnings | (85.44 M) | ||||
| Working Capital | (3.81 M) | ||||
About BriaCell Therapeutics Performance
Evaluating BriaCell Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BriaCell Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BriaCell Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 90.9 K | 95.5 K | |
| Return On Tangible Assets | (0.68) | (0.64) | |
| Return On Capital Employed | (1.06) | (1.11) | |
| Return On Assets | (0.67) | (0.64) | |
| Return On Equity | 4.84 | 5.08 |
Things to note about BriaCell Therapeutics performance evaluation
Checking the ongoing alerts about BriaCell Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BriaCell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BriaCell Therapeutics generated a negative expected return over the last 90 days | |
| BriaCell Therapeutics has high historical volatility and very poor performance | |
| BriaCell Therapeutics has some characteristics of a very speculative penny stock | |
| BriaCell Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (4.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BriaCell Therapeutics generates negative cash flow from operations |
- Analyzing BriaCell Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BriaCell Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining BriaCell Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BriaCell Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BriaCell Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BriaCell Therapeutics' stock. These opinions can provide insight into BriaCell Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BriaCell Stock Analysis
When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.